Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

52 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of mouse Pancreatic Intraepithelial Neoplasias (PanINs) with NF-κB Essential Modulator (NEMO) knockout against NEMO wild-type

ABSTRACT: The canonical NF-κB pathway is active in 70% of all pancreatic cancer cases and NF-κB Essential Modulator (NEMO) is essential for the activation of this pathway. In our study, we used KC mice, which express the oncogenic KRAS and develop precancerous lesions termed Pancreatic Intraepithelial Neoplasias (PanINs), and KNeC mice, which express the oncogenic KRAS and have NEMO deleted in their pancreatic cells. These mice were injected with cerulein to promote the development of pancreatitis (cerulein dosage= 50μg/kg). Cerulein was injected at 8 hourly intervals for 2 days in total. The first injection day was when mice reached their sixth week of age and the second injection day was 3 days after the first injection day. Both KC and KNeC mice developed PanINs. At the age of 10 months, pancreata of KC and KNeC mice were analyzed. Using laser capture microdissection, PanINs from both groups were excised and their transcriptome was analyzed though RNA-seq.

INSTRUMENT(S): RNeasy Micro Kit (QIAGEN #74004), DNBSEQ-G400, PALM Microbeam Rel. 4.9 with RoboMover microscope (Zeiss), NuGEN Trio low input RNA-seq

ORGANISM(S): Mus musculus

SUBMITTER: Miltiadis Tsesmelis

PROVIDER: E-MTAB-12433 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq of mouse Pancreatic Intraepithelial Neoplasias (PanINs) with NF-κB Essential Modulator (NEMO) knockout against NEMO wild-type

Project description:RNA-seq of mouse Pancreatic Intraepithelial Neoplasias (PanINs) with NF-κB Essential Modulator (NEMO) knockout against NEMO wild-type

| PRJEB58090 | ENA

Quantitative Analysis of PPARD mRNA-Seq Transcriptomes of Mouse KRAS Mutant Pancreatic Tissues by Next Generation Sequencing (NGS)

Project description:Pancreatic cancer is the most highly lethal disease with an increasing incidence. Accumulating evidence shows that as an initiating event of pancreatic tumorigenesis, mutant KRAS requires additional factors to promote pancreatic cancer progression. Peroxisome proliferator-activated receptor-delta/beta (PPAR-d) is a ligand-activating transcription factor that modulates many critical cellular functions and is upregulated in human pancreatic cancer tissues. To study PPAR-d's effects on mutant KRAS-initiated pancreatic tumorigenesis, we have generated a novel transgenic mouse model with simultaneously targeted PPAR-d overexpression and KrasG12D mutation (KRASmu) in pancreatic epithelial cells (called KC/Pd mice). Our preliminary data showed that PPAR-d ligand GW501516 strongly promoted pancreatic tumorigenesis in KRASmu mice (KC), and PPAR-d upregulation dramatically enhanced these effects in KC/Pd mice. However, molecular mechanisms by which PPAR-d and its synthetic ligand GW501516 promote KRASmu-initiated pancreatic tumorigenesis remains largely unknown. We have therefore performed genome-wide mRNA seq profiling analysis for pancreatic tissues from KC [WT] and KC/Pd (PD) mice fed GW501516 diet to discover the critical genes/pathways directly regulated by PPAR-d overactivation that accelerate pancreatic cancer progression. Pancreatic tissues of GW-treated KC/Pd (PD-GW) and KC (WT-GW) mice had distinctive differential expression patterns with 1498 differentially expressed genes (DEGs) according to a cut-off of p(Adj)<.05, including 709 upregulated DEGs and 789 downregulated DEGs. Furthermore, Gene set enrichment analyses of these 1498 DEGs using the ?Hallmark gene sets? category showed that the top enriched pathways included IL6-JAK-STAT3, inflammatory response, and KRAS signaling. Thus, the RNA-seq profiling analyses provide us important clues for molecular mechanisms by which PPAR-d overactivation promotes pancreatic cancer progression.

2022-03-02 | GSE176135 | GEO

IL-8 released from human pancreatic cancer and tumor associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy

Project description:Serum levels of interleukin-8 (IL-8) are increased in the serum of people with pancreatic cancer and associated with the loss of body weight and low muscle mass. We have identified that systemic (intraperitoneal) injection of IL-8 into mice induces significant skeletal muscle atrophy. Transcriptional profiling of muscle harvested from these same mice identified the genes and biological processes associated with this IL-8 induced atrophy including gene clusters related to chromatin modification, muscle cell differentiation, and ubiquitin ligase complex. In this dataset, we include the expression data obtained from the tibialis anterior muscle from vehicle-injected mice, KC-injected mice, and IL-8 injected mice. The purpose of this study was to identify the broader transcriptional networks changed in skeletal muscle in response to a systemic increase in IL-8 or KC.

2019-12-03 | GSE137990 | GEO

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation driven pancreatic cancer

Project description:To investigate the transcriptomic effects of iASPP deletion or p53 mutation in the KRASG12D background Pdx1-Cre was used to delete iASPP in oncogenic KRASG12D expressing (KC) background to generate KC;iASPPΔ8/Δ8 mice. KC and KC;iASPPΔ8/Δ8 mice were then crossed with mice containing a p53R172H allele (equivalent to human p53 hotspot mutation R175H) to generate KPC and KPC;iASPPΔ8/Δ8 cohorts. Primary cell cultures were then derived from pancreatic ductal adenocarcinoma tissue for RNA-seq.

2023-07-06 | GSE226595 | GEO

RNA-Seq of genetically engineered mouse models (GEMMs) of PDA with or without KRAS and/or TP53 mutations

Project description:We profile gene expression upon WT, KC and KPC mice of pancreatic cancer

2022-12-20 | GSE190903 | GEO

H3K27ac ChIP-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:We profile H3K27ac signals in WT, KC and KPC mice of pancreatic cancer

2022-12-20 | GSE190901 | GEO

ATAC-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:We profile chromatin accessibility signals in WT, KC and KPC mice of pancreatic cancer

2022-12-20 | GSE190900 | GEO

Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells

Project description:Development of systems that reconstitute hallmark features of human pancreatic intraepithelial neoplasia (PanINs), the precursor to pancreatic ductal adenocarcinoma, could generate new strategies for early diagnosis and intervention. However, human cell-based PanIN models with defined mutations are unavailable. Here, we report that genetic modification of primary human pancreatic cells leads to development of lesions resembling native human PanINs. Primary human pancreas duct cells harbouring oncogenic KRAS and induced mutations in CDKN2A, SMAD4 and TP53 expand in vitro as epithelial spheres. After pancreatic transplantation, mutant clones form lesions histologically similar to native PanINs, including prominent stromal responses. Gene expression profiling reveals molecular similarities of mutant clones with native PanINs, and identifies potential PanIN biomarker candidates including Neuromedin U, a circulating peptide hormone. Prospective reconstitution of human PanIN development from primary cells provides experimental opportunities to investigate pancreas cancer development, progression and early-stage detection.

2017-03-14 | GSE88997 | GEO

Effect of NF-kappaB activation in bone marrow stromal cells co-cultured with CLL cells

Project description:Tumor cell survival critically depends on heterotypic communication with benign cells in the microenvironment. Here we describe a novel survival signaling pathway activated in stromal cells by contact to B-cells from chronic lymphocytic leukemia (CLL) patients. The expression of PKC-M-NM-2II and the subsequent activation of NF-M-NM-:B in bone marrow stromal cells is a prerequisite to support the survival of malignant B-cells. PKC-M-NM-2 knockout mice are insusceptible to CLL-transplantations, underscoring the in vivo significance of the PKC-M-NM-2II- NF-M-NM-:B signaling pathway in the tumor microenvironment. Upregulated stromal PKC-M-NM-2II in biopsies from CLL, breast- and pancreatic- cancer patients suggest that this pathway may commonly be activated in a variety of malignancies. We used microarrays to determine Nemo/ IKK-gamma dependent gene expression changes in bone marrow stromal cells (BMSCs) induced by co-culturing with leukemic B-cells (CLL) We compared mouse BMSC cells from Nemo knockout cells (Nemo+CRE) and Nemo wild type cells (Nemo-CRE) co-cultured for 5 days with leukemic B-cells microarray analysis on Affymetrix MG-430_2.0 arrays..

2013-03-08 | E-GEOD-36415 | biostudies-arrayexpress

RNA-Seq of isolated pancreatic stellate cells from mice with autoimmune pancreatitis and chronic pancreatitis

Project description:Autoimmune pancreatitis (AIP) is a disease with unclear immunologic triggers. This study shows that the pancreatic stellate cells(PSCs) are involved in the regulation of the immune response and can cause autoimmunity when the NF-κB signalling in these cells is disrupted. The PSCs were isolated from animals which show autoimmune pancreatitis (NEMO knockout group) or chronic pancreatitis (NEMO wildtype group).

2023-06-30 | E-MTAB-7337 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data